Immunogen Inc.
830 Winter Street
Waltham,
MA 02451-1477
United States - Map
Phone: 781-895-0600
Fax: 781-895-0611
Web Site: http://www.immunogen.com
| ImmunoGen, Inc. engages in the research and development of antibody-based anticancer therapeutics in the United States. The company develops therapeutics for the treatment of cancer using its Targeted Antibody Payload (TAP) technology, which uses antibodies to deliver a potent cytotoxic agent. Its products include Trastuzumab-DM1, a Phase II clinical trial product for the treatment of metastatic breast cancer; IMGN901, a Phase I clinical trial product to treat hematological malignancies, including multiple myeloma, small-cell lung cancer, Merkel cell carcinoma, and other cancers of neuroendocrine origin; SAR3419, a Phase I clinical trial product for the treatment of B-cell hematological malignancies, including non-Hodgkins lymphoma; and IMGN388 and BIIB015, which are in Phase I clinical trials for the treatment of solid tumors. The companys products also comprise BT-062, a Phase I clinical trial product targeting multiple myeloma; SAR566658, a preclinical trail product for the treatment of breast, ovarian, and other solid tumors; SAR650984, a preclinical trail product to treat hematological malignancies; and TAP and other compounds. It has licensing or collaboration agreements with sanofi-aventis; Genentech, Inc.; Biotest AG; Bayer HealthCare AG; Biogen Idec; Amgen, Inc.; Centocor, Inc.; Cytovance Biologics LLC; Laureate Pharma, Inc.; BioInvent International AB; Diosynth RTP, Inc.; and Societa Italiana Corticosteroidi S.r.l. ImmunoGen was founded in 1981 and is headquartered in Waltham, Massachusetts. |
|
| Key Statistics |
| |
| | Pay | Exercised | Mr. Daniel M. Junius , 57
Chief Exec. Officer, Pres |
$
551.00K |
$
0 | Mr. Gregory D. Perry , 48
Chief Financial Officer, Principal Accounting Officer, Sr. VP and Treasurer |
$
179.00K |
$
0 | Dr. John M. Lambert Ph.D., 58
Chief Scientific Officer and Exec. VP of R&D |
$
418.00K |
$
88.00K | Dr. James J. O'Leary MD, 45
Chief Medical Officer and VP |
$
321.00K |
$
0 | Mr. Craig Barrows , 54
VP, Sec. and Gen. Counsel |
N/A
| N/A |
|
|
|
Dollar amounts are as of
31-Dec-09
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
1.29% Nasdaq 
Profile
